Information:
Fel:
ID
23930
Beskrivning
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM); ODM derived from: https://clinicaltrials.gov/show/NCT00529191
Länk
https://clinicaltrials.gov/show/NCT00529191
Nyckelord
Versioner (1)
- 2017-07-18 2017-07-18 -
Uppladdad den
18 juli 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Type 1 Diabetes NCT00529191
Eligibility Type 1 Diabetes NCT00529191
- StudyEvent: Eligibility
Similar models
Eligibility Type 1 Diabetes NCT00529191
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
individuals 10-19 years of age (tanner stage ii or greater),
boolean
C0429602 (UMLS CUI [1,1])
C0429602 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
C0429602 (UMLS CUI [1,2])
C0001779 (UMLS CUI [1,3])
ID.2
Item
the presence of one or more serum antibodies to islet cell proteins (anti- glutamic acid decarboxylase [gad], islet antigen 2 or insulin autoantibodies) as assessed in standard practice,
boolean
C1522529 (UMLS CUI [1,1])
C3203592 (UMLS CUI [1,2])
C3203592 (UMLS CUI [1,2])
ID.3
Item
diagnosis of t1dm within the 8 weeks prior to study entry
boolean
C0011854 (UMLS CUI [1])
ID.4
Item
peak stimulated c-peptide level >0.2pmol/ml following mixed meal tolerance test (mmtt) performed at least 3 weeks after diagnosis,
boolean
C0202100 (UMLS CUI [1])
ID.5
Item
females of reproductive potential must not plan on conceiving a child during the treatment program, and agree to use a medically accepted form of contraception
boolean
C0700589 (UMLS CUI [1])
ID.6
Item
subjects currently receiving cyclosporine, fibric acid derivatives, niacin (nicotinic acid), erythromycin, clarythromycin, nefazodone, itraconazole, ketoconazole or protease inhibitors,
boolean
C0010592 (UMLS CUI [1,1])
C4020588 (UMLS CUI [1,2])
C0027996 (UMLS CUI [1,3])
C0014806 (UMLS CUI [1,4])
C0055856 (UMLS CUI [1,5])
C0068485 (UMLS CUI [1,6])
C0022625 (UMLS CUI [1,7])
C0033607 (UMLS CUI [1,8])
C0064113 (UMLS CUI [1,9])
C4020588 (UMLS CUI [1,2])
C0027996 (UMLS CUI [1,3])
C0014806 (UMLS CUI [1,4])
C0055856 (UMLS CUI [1,5])
C0068485 (UMLS CUI [1,6])
C0022625 (UMLS CUI [1,7])
C0033607 (UMLS CUI [1,8])
C0064113 (UMLS CUI [1,9])
ID.7
Item
pregnancy or breast-feeding,
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])
ID.8
Item
clinical aids, aids related syndrome (ars) or known positive hiv serology,
boolean
C0001175 (UMLS CUI [1,1])
C0019682 (UMLS CUI [1,2])
C0019682 (UMLS CUI [1,2])
ID.9
Item
subjects treated with immunosuppressive therapy in the past 12 months,
boolean
C0021079 (UMLS CUI [1])
ID.10
Item
subjects receiving glucocorticoid therapy or therapy other than insulin that is likely to affect glucose homeostasis (such as sulfonylureas, thiazolidinediones, metformin or amylin),
boolean
C0744425 (UMLS CUI [1,1])
C1326961 (UMLS CUI [1,2])
C1326961 (UMLS CUI [1,2])
ID.11
Item
subjects with other autoimmune diseases, except autoimmune thyroid disease,
boolean
C0004364 (UMLS CUI [1])
ID.12
Item
subjects with any illness that might complicate diabetes management or preclude treatment with atorvastatin,
boolean
C0221423 (UMLS CUI [1])
ID.13
Item
transplant recipients,
boolean
C0376387 (UMLS CUI [1])
ID.14
Item
evidence of liver dysfunction or myopathy
boolean
C0026848 (UMLS CUI [1,1])
C0086565 (UMLS CUI [1,2])
C0086565 (UMLS CUI [1,2])